Intrexon Actobiotics: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Intrexon Actobiotics
Largest movements
- Receivables within one year -€1.0m
down €1.0m (-10.5%), from €9.7m to €8.7m
of which Trade receivables: -€1.0m
- Accrued charges and deferred income -€694,633
down €694,633 (-98.6%), from €704,835 to €10,202
- Profit (loss) carried forward -€372,153
down €372,153 (-0.8%), from -€46.8m to -€47.2m
- Staff costs -€3.3m
no longer reported in 2025 (was €3.3m)
- Financial charges +€1.1m
up €1.1m (+413%), from €255,886 to €1.3m
- Gross operating margin -€826,551
down €826,551, from €609,502 to -€217,049
- Financial income +€470,730
up €470,730 (+68.4%), from €687,797 to €1.2m
- Write-downs -€28,732
no longer reported in 2025 (was €28,732)
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €9,777,708 | €8,762,904 | -€1.0m | -10.4% |
| Current assets | 29/58 | €9,777,708 | €8,762,904 | -€1.0m | -10.4% |
| Amounts receivable within one year | 40/41 | €9,688,436 | €8,668,414 | -€1.0m | -10.5% |
| Trade receivables | 40 | €9,628,323 | €8,621,876 | -€1.0m | -10.5% |
| Other amounts receivable | 41 | €60,113 | €46,538 | -€13,575 | -22.6% |
| Cash at bank and in hand | 54/58 | €33,547 | €70,954 | +€37,407 | +112% |
| Deferred charges and accrued income | 490/1 | €55,724 | €23,536 | -€32,188 | -57.8% |
| Total equity and liabilities | 10/49 | €9,777,708 | €8,762,904 | -€1.0m | -10.4% |
| Equity | 10/15 | €8,964,162 | €8,592,009 | -€372,153 | -4.2% |
| Contributions | 10/11 | €55,779,052 | €55,779,052 | = | 0.0% |
| Capital | 10 | €6,347,796 | €6,347,796 | = | 0.0% |
| Issued capital | 100 | €12,347,796 | €12,347,796 | = | 0.0% |
| Uncalled capital | 101 | €6,000,000 | €6,000,000 | = | 0.0% |
| Contributions outside capital | 11 | €49,431,256 | €49,431,256 | = | 0.0% |
| Share premium | 1100/10 | €49,431,256 | €49,431,256 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€46,814,891 | -€47,187,043 | -€372,153 | -0.8% |
| Amounts payable | 17/49 | €813,546 | €170,895 | -€642,651 | -79.0% |
| Amounts payable within one year | 42/48 | €108,710 | €160,692 | +€51,982 | +47.8% |
| Trade debts | 44 | €73,619 | €109,034 | +€35,414 | +48.1% |
| Suppliers | 440/4 | €73,619 | €109,034 | +€35,414 | +48.1% |
| Taxes, remuneration and social security | 45 | €35,091 | - | -€35,091 | |
| Remuneration and social security | 454/9 | €35,091 | - | -€35,091 | |
| Other amounts payable | 47/48 | - | €51,659 | +€51,659 | |
| Accrued charges and deferred income | 492/3 | €704,835 | €10,202 | -€694,633 | -98.6% |
| Non-recurring operating income | 76A | €12,972 | €19,295 | +€6,324 | +48.7% |
| Remuneration, social security and pensions | 62 | €3,285,749 | - | -€3.3m | |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €28,732 | - | -€28,732 | |
| Other operating charges | 640/8 | €15,429 | €1,150 | -€14,280 | -92.5% |
| Non-recurring operating charges | 66A | €230,561 | - | -€230,561 | |
| Gross operating margin | 9900 | €609,502 | -€217,049 | -€826,551 | |
| Operating profit (loss) | 9901 | -€2,950,970 | -€218,199 | +€2.7m | +92.6% |
| Financial income | 75/76B | €687,797 | €1,158,527 | +€470,730 | +68.4% |
| Recurring financial income | 75 | €687,797 | €1,158,527 | +€470,730 | +68.4% |
| Financial charges | 65/66B | €255,886 | €1,312,481 | +€1.1m | +413% |
| Recurring financial charges | 65 | €255,886 | €1,312,481 | +€1.1m | +413% |
| Profit (loss) for the period before taxes | 9903 | -€2,519,059 | -€372,153 | +€2.1m | +85.2% |
| Income taxes | 67/77 | €1,865 | - | -€1,865 | |
| Profit (loss) for the period | 9904 | -€2,520,924 | -€372,153 | +€2.1m | +85.2% |
| Profit (loss) for the period to be appropriated | 9905 | -€2,520,924 | -€372,153 | +€2.1m | +85.2% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 31 October 2026 via checked.be.